Distinct efficacy of pegylated-interferon α2a and α2b during treatment of essential thrombocythemia

Int J Hematol. 2013 Mar;97(3):438-9. doi: 10.1007/s12185-013-1288-x. Epub 2013 Feb 12.
No abstract available

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Amino Acid Substitution
  • Antiviral Agents / administration & dosage*
  • Female
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Janus Kinase 2 / genetics
  • Janus Kinase 2 / metabolism
  • Middle Aged
  • Mutation, Missense
  • Polyethylene Glycols / administration & dosage*
  • Recombinant Proteins / administration & dosage
  • Thrombocythemia, Essential / blood
  • Thrombocythemia, Essential / drug therapy*
  • Thrombocythemia, Essential / genetics

Substances

  • Antiviral Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Polyethylene Glycols
  • JAK2 protein, human
  • Janus Kinase 2
  • peginterferon alfa-2b
  • peginterferon alfa-2a